PMID- 37861543
OWN - NLM
STAT- MEDLINE
DCOM- 20231030
LR  - 20231030
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 42
DP  - 2023 Oct 20
TI  - Role of MCP-1/CCR2 axis in renal fibrosis: Mechanisms and therapeutic targeting.
PG  - e35613
LID - 10.1097/MD.0000000000035613 [doi]
LID - e35613
AB  - Renal fibrosis is a common pathological manifestation in various chronic kidney 
      diseases. Inflammation plays a central role in renal fibrosis development. Owing 
      to their significant participation in inflammation and autoimmunity, chemokines 
      have always been the hot spot and focus of scientific research and clinical 
      intervention. Among the chemokines, monocyte chemoattractant protein-1 (MCP-1), 
      also known as C-C motif chemokine ligand 2, together with its main receptor C-C 
      chemokine receptor type 2 (CCR2) are important chemokines in renal fibrosis. The 
      MCP-1/CCR2 axis is activated when MCP-1 binds to CCR2. Activation of MCP-1/CCR2 
      axis can induce chemotaxis and activation of inflammatory cells, and initiate a 
      series of signaling cascades in renal fibrosis. It mediates and promotes renal 
      fibrosis by recruiting monocyte, promoting the activation and 
      transdifferentiation of macrophages. This review summarizes the complex physical 
      processes of MCP-1/CCR2 axis in renal fibrosis and addresses its general 
      mechanism in renal fibrosis by using specific examples, together with the 
      progress of targeting MCP-1/CCR2 in renal fibrosis with a view to providing a new 
      direction for renal fibrosis treatment.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - He, Shiyang
AU  - He S
AD  - The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China.
AD  - Basic and Applied Laboratory of Traditional Chinese Medicine, Zunyi Medical 
      University Zhuhai Campus, Zhuhai, China.
FAU - Yao, Lan
AU  - Yao L
AD  - The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China.
AD  - Blood Purification Center, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Li, Jun
AU  - Li J
AUID- ORCID: 0009-0007-6874-5235
AD  - The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China.
AD  - Basic and Applied Laboratory of Traditional Chinese Medicine, Zunyi Medical 
      University Zhuhai Campus, Zhuhai, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (Receptors, CCR2)
RN  - 0 (CCL2 protein, human)
SB  - IM
MH  - Humans
MH  - Chemokine CCL2/metabolism
MH  - Chemokines/metabolism
MH  - Fibrosis
MH  - Inflammation
MH  - *Kidney Diseases
MH  - *Receptors, CCR2/metabolism
PMC - PMC10589562
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/10/20 12:44
MHDA- 2023/10/23 01:18
PMCR- 2023/10/20
CRDT- 2023/10/20 10:33
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/10/20 12:44 [pubmed]
PHST- 2023/10/20 10:33 [entrez]
PHST- 2023/10/20 00:00 [pmc-release]
AID - 00005792-202310200-00070 [pii]
AID - 10.1097/MD.0000000000035613 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Oct 20;102(42):e35613. doi: 
      10.1097/MD.0000000000035613.